Aditya Parikh

Consultant Urologist Shyam Speciality Hospital Ahmedabad,

Fellowship in Pelvic uro-oncology and Robotics (UCLH, London) 2023-2024,

Mpuh Nadiad Uro(2019-2022)

[Aditya Parikh @adityaparikh_]

. Having him beside me in the OT made it unforgettable. 🙏
Grateful to the bedside & anesthesia teams and the @IntuitiveSurg team

[Aditya Parikh @adityaparikh_]

Rare privilege this week: performed the inaugural case on the new Da Vinci Xi at Sterling Hospitals, Ahmedabad — a robotic ureteric reimplant in a redo patient.
Full circle moment: my father, @DrKandarp_Uro , inaugurated Sterling's first robot years ago.

[Aditya Parikh @adityaparikh_]

@AhmedINazer @MAlKhameesMD @Aldughiman_MD @sbinhamrii @SMCH_Riyadh Amazing! Would love to see the full video!

[Aditya Parikh @adityaparikh_]

@RaviBarodUrol Sincere condolences Ravi

[Aditya Parikh @adityaparikh_]

@drenriquegrande @TheZouq Exciting times for bladder cancer patients and doctors ahead. Hopefully this combo revolutionizes the management of disease!

[Aditya Parikh @adityaparikh_]

Absolutely incredible @abhisingh82 sir

[Abhishek singh @abhisingh82]

Ureteric avulsion is one of the most challenging situation that a urologist can face.
Also, when faced with such a situation, a good reconstruction is a must : sharing a link of robotic Ileal replacement on the left side using a single dock .

https://t.co/kaA0TChnsf

[Aditya Parikh @adityaparikh_]

Was an excellent initiative! So happy to have been part of this

[IITRAM_Official @IITRAM191595]

The session witnessed active participation and meaningful interaction, making it a valuable and informative experience for all attendees.

@adityaparikh_

[IITRAM_Official @IITRAM191595]

The talk will be delivered by Dr. Aditya Parikh, a distinguished Uro-oncologist and Robotic Surgeon at Shyam Speciality Hospital, Ahmedabad. With advanced fellowship training from University College London Hospitals (UCLH) and MPUH,

[IITRAM_Official @IITRAM191595]

Dr. Parikh specializes in the intersection of complex surgical care and medical technology.

@adityaparikh_

#IITRAM | #Ahmedabad | #Gujarat | #WomenDevelopmentCell | #WomensHealth | #CancerAwareness | #WomensHealthMatters | #HealthAwareness | #Urology | #Healthcare | #HealthTalk

[Aditya Parikh @adityaparikh_]

@LauraBukavinaMD Seems like an interesting technique. Is there a video of this technique for reference?

[Aditya Parikh @adityaparikh_]

@lee_c_zhao Brilliantly written. Thoughtful, insightful. The writing is as artistic as your surgeries!

[Ruben De Groote @Ruben_De_Groote]

MUST READ for urologist and radonc!

Real world data on late GU toxicity after radiotherapy for prostate cancer

Short term is underestimation of the real burden for the patient. Important when counselling patients for decision making.

@aleantonellibs1 @RicBertolo

[Aditya Parikh @adityaparikh_]

What a pleasure Professor Traxer to have had your expertise in demonstrating challenging cases and pushing the boundaries forward for at AIE 2025 @DrKandarp_Uro

[Olivier Traxer @OTRAXER]

BN179: INDIA, Dec.19th-2025 very privileged to perform the very first Clinical evaluation of the new TFL Laser of IPG Medical : «The TFL LUROS 60s ». With new STONE SENSE- MRP (Minimal Retropulsion pulse) and New Fragmentation Pulse modulation: 20 to 30 J and 1Hz for kidney stone

[Olivier Traxer @OTRAXER]

BN179: INDIA, Dec.19th-2025 very privileged to perform the very first Clinical evaluation of the new TFL Laser of IPG Medical : «The TFL LUROS 60s ». With new STONE SENSE- MRP (Minimal Retropulsion pulse) and New Fragmentation Pulse modulation: 20 to 30 J and 1Hz for kidney stone

[Aditya Parikh @adityaparikh_]

@free_ai_guides Gemini

[Aditya Parikh @adityaparikh_]

@aiwithjainam AI

[Harsha Bhogle @bhogleharsha]

World Champions. At the stroke of the midnight hour India awakes to history. This is a moment in time that will change the course of the women's game.

[Dr Rishabh Jain @DrRishabhOnco]

“Can surgery still matter in metastatic prostate cancer?” 🩺

💥 RAMPP trial says maybe yes - even in low-volume mHSPC.

🧪 Design:
De novo low-volume mHSPC (≤5 bone mets ± nodes)
👥 Fit for RP + systemic therapy (ADT ± ARPI)
🆚 Radical prostatectomy (RP) + BST vs BST alone
🎯 Primary: Cancer-specific mortality (CSM)

📊 Results (~5 yrs):
•🩸 CSM: 13% vs 23% → HR 0.39, p=0.045 ✅
•🧭 Progression: 59% vs 60% (NS)
•💀 OS: 81% vs 74% (p=0.13)
•⚙️ Complications ≥ G3: 14%, no peri-op deaths

💬 Takeaway:
RP added to BST reduced CSM in low-volume mHSPC — mirroring the STAMPEDE RT signal 🔁
But OS gain unproven → discuss in MDT before adopting.

📖 Graefen et al. European Urology 2025.

🔗DOI: https://t.co/XMhMFVLHPW

#OncoTwitter #ProstateCancer #mHSPC #UroOnc
@OncoAlert @myESMO @ESMO_Open @ASCO @EuropeanUrology @EUplatinum @Uroweb

[Aditya Parikh @adityaparikh_]

@yang_kunlin Excellent! Thankyou for letting me know!